Project Grant R44ES033579

Award Date 7/15/21
Completion Date 7/31/25
Dollars Obligated $2.8M
Federal Grant Program
93.113
Assistance Type
Project Grant
Place of Performance
Austin, TX 78731, USA
Similar Awards
This Project Grant awarded by the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health (CFDA 93.113) program provides $295,734 to Litron Laboratories Ltd, a for-profit biotechnology company, to develop a comprehensive hen's egg model for genotoxicity testing. The project aims to create a non-animal, metabolically-active in vitro system that can effectively assess the genotoxic risk of pharmaceuticals and industrial chemicals. Key deliverables include...
This Project Grant award from the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health (CFDA 93.113) program provides $605,550 in funding to the University of Toledo Health Science Campus Division to explore the effects of developmental exposure to the pyrethroid pesticide deltamethrin in the prairie vole as a model for understanding environmental risk factors for autism and other neurodevelopmental disorders. The key products and services to be delivered...
This $500,000 Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program aims to develop a novel human stem cell-based microfluidic developmental toxicology platform. The University of Michigan will receive funding from September 2022 to August 2024 to conduct technological development of a repeatable, controllable, high-throughput microfluidic system for generating three-dimensional multicellular organoid models for toxicity testing. The platform seeks...
This $553,708 Project Grant award from the National Institute of Environmental Health Sciences (NIEHS), under the Environmental Health (CFDA 93.113) program, aims to advance the development of a community-led Zebrafish Toxicology Phenotype Atlas. The key products and services to be delivered include: Designing and deploying a standardized Toxicophenotype Data Model to improve data compatibility across zebrafish toxicology studies and domains. Creating a Toxicophenotype Annotation Toolkit to...
The U.S. Department of Agriculture's National Institute of Food and Agriculture has awarded a $175,000 Project Grant under the Small Business Innovation Research (SBIR) Program to Vivoverse, LLC, a woman-owned small business. The funding will support the development of a high-resolution imaging platform and automated analysis pipeline to rapidly assess the health benefits and potential toxicity of food ingredients, herbal preparations, and plant-derived products using the C. elegans model...
This $900,804 Project Grant award from the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health (CFDA 93.113) federal grant program supports the development and validation of an integrated microphysiological screening platform (MPS) with "virtual human" models to assess chemical toxicity. The key products and services to be delivered include: A 96-well MPS screening platform that combines elements of the awardee's commercial 48-well MPS with highly...
This $249,943 Project Grant award from the National Institutes of Health's National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health (CFDA 93.113) program supports the research and development of an adverse outcome pathway-focused mechanistic inference tool for 'omics data using semantic knowledge graphs. The key products and services to be delivered through this one-year award include: Improving statistical models to better quantify adverse outcome pathway...
This Project Grant award from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) provides $309,251 to Expanse Bio LLC to develop an ex vivo microfluidic organ perfusion device for long-term culture and assessment of whole ovaries. The goal is to create a more physiologically relevant model for evaluating the ovotoxicity (ovarian damage) potential of drug candidates, particularly...
This Project Grant award from the National Institutes of Health (NIH) Research Infrastructure Programs (CFDA 93.351) provides $270,428 to TEO Therapeutics Incorporated, a small disadvantaged business, to develop a biomimetic platform for more efficient pharmaceutical drug development in oncology. The key products and services to be delivered include: Refining and testing a proof-of-concept hardware product line for a Shell-Free Quail Xenograft Assay, optimizing throughput and assessing...
The National Institute of Environmental Health Sciences (NIEHS) awarded Nexilico, Inc. a $275,765 Project Grant (CFDA 93.113 - Environmental Health) to develop a predictive computational-experimental platform to characterize microbial biotransformation of xenobiotic compounds and identify naturally occurring gut microbial strains that can mitigate xenobiotic toxicity as novel probiotics. The project aims to provide cost-effective yet accurate predictions to identify microbial species capable...

THE NEXT-GENERATION DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY (DART) ASSAY USING HIGH-CONTENT ANALYSIS OF GENETICALLY DIVERSE C. ELEGANS POPULATIONS - 1 MODERN TOXICOLOGY ASSESSMENT OF CHEMICALS IS UNDER PRESSURE FROM BOTH SCIENTIFIC AND SOCIAL SOURCES. TRADITIONAL 2 STUDY MODELS USING SMALL NUMBERS OF HIGHLY INBRED MAMMALS FAIL TO REFLECT THE WIDE GENETIC, GEOGRAPHIC, AND 3 DEMOGRAPHIC VARIATION UNDERLYING DIFFERING POPULATION-SPECIFIC RESPONSES TO ENVIRONMENTAL TOXICANTS AND DRUGS. 4 SECONDLY, LONG-STANDING PUBLIC PRESSURE TO REDUCE THE USE OF ANIMALS IN SAFETY TESTING HAS RESULTED IN REGULATORY 5 DIRECTIVES TO BAN THE USE OF ANIMAL STUDIES IN APPROVALS OF NEW CHEMICAL ENTITIES AND EXISTING CHEMICAL PRODUCT 6 RE-REGISTRATIONS BY 2035. THIS PRESSURE ALONG WITH CONTINUAL ADVANCES IN LIFE SCIENCE TECHNOLOGY HAS LED TO THE 7 DEVELOPMENT OF NEW APPROACH METHODS (NAMS) INCLUDING IN VITRO, ETHICAL IN VIVO, AND IN SILICO METHODS. 8 ENVIRONMENTAL JUSTICE, ESPECIALLY FOR VULNERABLE FENCE LINE COMMUNITIES AT MUCH GREATER RISK OF ENVIRONMENTAL 9 EXPOSURE TO CHEMICALS, HIGHLIGHTS THE NEED TO INCLUDE VULNERABLE POPULATIONS IN TOXICOLOGY STUDIES. MODELING 10 POPULATION VARIATION IN TOXIC RESPONSES AT THE NECESSARY THROUGHPUTS IS NOT FEASIBLE USING OUTBRED IN VIVO 11 MAMMALIAN MODELS, AND IN VITRO METHODS ARE UNSUITABLE FOR ASSAYS REQUIRING COMPLETE ORGANISMS SUCH AS 12 DEVELOPMENTAL AND REPRODUCTIVE TOXICITY (DART). USING ITS NOVEL VIVOCHIP DEVICE, VIVOVERSE PROPOSES A NAM 13 FOR DART TESTING BASED ON THE MICROSCOPIC, SOIL-DWELLING NEMATODE, CAENORHABDITIS ELEGANS. C. ELEGANS HAS A 14 SIMPLE CULTURING PROTOCOL, ABILITY TO PRODUCE 300 PROGENIES PER ADULT, CONSERVED TOXICOLOGY PATHWAYS WITH 15 HUMANS, INTACT GERMLINE WITH TRACTABLE IN UTERO EMBRYOGENESIS, IS A NON-SENTIENT INVERTEBRATE WITH A 3-DAY LIFE 16 CYCLE THAT IS NOT SUBJECT TO ANIMAL WELFARE LEGISLATION, AND HAS WELL-CHARACTERIZED PANELS OF SEVERAL HUNDRED 17 NATURALLY OCCURRING STRAINS WITH DIVERSE GENETIC BACKGROUNDS, MAKING IT A HIGHLY SUITABLE SMALL ANIMAL MODEL FOR 18 DART ASSAYS. THE VIVOCHIP IS A MICROFLUIDIC-BASED IMAGING PLATFORM UNIQUELY FACILITATING HIGH-THROUGHPUT 19 TOXICOLOGY ASSAYS WITH C. ELEGANS, USING HIGH-RESOLUTION IMAGING TO QUANTIFY RELEVANT PHENOTYPIC ENDPOINTS IN 20 ~1,000 ANIMALS PER CHIP. IN AIM 1, WE WILL DEVELOP A NEW VIVOCHIP SPECIFICALLY FOR DART TESTING THAT ALLOWS RAPID 21 IMMOBILIZATION OF ~1,500 C. ELEGANS OF WIDELY VARYING SIZES. WE WILL ESTABLISH AN AI/ML-ASSISTED PIPELINE FOR 22 AUTOMATED ANALYSIS OF HIGH-RESOLUTION, ON-CHIP IMAGES OF IN UTERO, BODY, AND ORGAN PHENOTYPES RELEVANT TO DART. 23 IN AIM 2, WE WILL DEVELOP A GLP-QUALIFIED DART ASSAY THAT SURVEYS 12 GENETICALLY DIVERSE STRAINS AND 24 DEMONSTRATE STRAIN AND AGE-SPECIFIC SENSITIVITY FOR TWO REFERENCE CHEMICALS. IN AIM 3, WE WILL COMPARE DART 25 ASSESSMENTS WITH OUR PANEL OF 12 STRAINS AND TWO SENSITIZED MUTANTS, WITH PUBLISHED DATA FOR CHEMICALS OF 26 SIGNIFICANCE TO STAKEHOLDERS, TO DEMONSTRATE THE VALUE OF OUR ASSAY. WITH A MORE SENSITIVE DART ASSAY USING 27 HIGH-CONTENT READOUTS OF IN UTERO EFFECTS FROM TWELVE GENETICALLY DIVERSE BACKGROUNDS, WE EXPECT TO IMPROVE THE 28 KNOWN SAFETY PREDICTION ACCURACIES OF C. ELEGANS WHEN COMPARED TO HIGHER MAMMALIAN MODELS. ARMED WITH 29 SUCH DATA, WE WILL PRESENT OUR CASE STUDY TO THE REGULATORY AGENCIES FOR FORMAL RISK ANALYSIS, AND IN DUE COURSE, 30 FULL ACCEPTANCE OF C. ELEGANS AS AN ALTERNATIVE ANIMAL MODEL FOR DART, MAKING AN IMPACT ON MANY INDUSTRIES.

Posted 7/26/23, 12:00 AM